Investing.com - Effector Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Effector Therapeutics announced earnings per share of $-0.230 on revenue of $867K. Analysts polled by Investing.com anticipated EPS of $-0.173 on revenue of $642.2K.
Effector Therapeutics shares are down 5.02% from the beginning of the year, still down 95.77% from its 52 week high of $11.82 set on November 9, 2021.
Effector Therapeutics follows other major Healthcare sector earnings this month
Effector Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar